Background: Recently, evidence of cardio-protection and reduction in mortality due to the use of volatile agents during cardiac surgery led to an increase in their use during cardiopulmonary bypass (CPB). These findings seem to be enhanced when the volatile agents are used during all the surgical procedure, including the CPB period. Aims: Since the administration of volatile agents through CPB can be beneficial to the patients, we decided to review the use of volatile agents vaporized in the CPB circuit and to summarize some tricks and tips of this technique using our 10-year experience of Brazilian and Italian centers with a large volume of cardiac surgeries. Study Setting: Hospital. Methods: A literature review. Results: During the use of the volatile agents in CPB, it is very important to analyze all gases that come in and go out of the membrane oxygenators. The proper monitoring of inhaled and exhaled fraction of the gas allows not only monitoring of anesthesia level, but also the detection of possible leakage in the circuit. Any volatile agent in the membrane oxygenator is supposed to pollute the operating theater. This is the major reason why proper scavenging systems are always necessary when this technique is used. Conclusion: While waiting for industry upgrades, we recommend that volatile agents should be used during CPB only by skilled perfusionists and physicians with the aim to reduce postoperative morbidity and mortality.

Key words: Anesthesia; Cardiac surgery; Cardiopulmonary bypass; Sevoflurane; Volatile anesthetic

INTRODUCTION

The use of volatile anesthetic agents during cardiopulmonary bypass (CPB) was described for the 1st time about 40 years ago.[1] Originally, volatile agents were vaporized and administered in the early-generation bubble oxygenators. Today, most cardiac surgery interventions are performed with standard membrane oxygenators. Unfortunately, the newest CPB machines are not equipped routinely for the use of these anesthetic agents, and this means that we still need to adapt anesthetic vaporizers in the bypass circuit.

Some studies showed an evidence of cardioprotection and reduction in mortality due to the use of volatile agents during cardiac surgery.[2-6] These findings seems to be enhanced when the volatile agents are used during all the surgical procedure, including the period of CPB.[7]
Since the administration of volatile agents through CPB can be beneficial to the patients, we decided to review the use of volatile agents vaporized in the CPB circuit and to summarize some tricks and tips of this technique in our 10-year experience of Brazilian and Italian centers with a large volume of cardiac surgeries.

Table 1 summarizes the problems that we found in our extensive experience that can be related to the use of volatile agents vaporized in the CPB circuit. All these problems are associated to the vaporizer and to the analysis of the exhaled gases from the membrane oxygenator.

Until now, the technique of the use of volatile agents during CPB is an adaptation which includes the volatile agent vaporized into the circuit of the CPB machine mixed with the fresh gas flow (oxygen and compressed

| Problem | Cause | Solution |
|---------|-------|----------|
| 1. Insufficient blood oxygenation | Vaporizer not correctly put on the stirrup | Reposition the vaporizer correctly on the stirrup in order to avoid gas flux leakage |
| | Breath in fraction Luer Lock not correctly closed | Connect the breathe in reading line or a little plug in order to avoid gas leak |
| 2. No inspired fraction reading gas | a. Reading line not positioned | Place a reading line |
| | b. Broken reading line | Place a new reading line |
| | c. Tap (if present) not correctly turned | Turn the tap in the direction of the monitoring |
| | d. Empty vaporizer | Reload the vaporizer |
| | e. Switched off vaporizer | The gas vaporizer is an electric supply and it must be connected to the net or to a new light socket that works properly |
| | f. Vaporizer not correctly positioned on the stirrup | Correctly reposition the vaporizer on the stirrup |
| | g. Nonelectronic vaporizer run out of gas even though the sentinel column is sufficient | Reload the vaporizer (see problem 9) |
| 3. Malfunctioning of the vaporizer alarm | The electronic vaporizer was put on a stirrup where the gas input and output were inverted | Invert the gas input and output (air/oxygen) following the indication on the stirrup |
| 4. The vaporizer does not function and the lights are flashing simultaneously | The electronic vaporizer did not pass the initial check because it was positioned on a stirrup not in axis, but turned forward | While waiting for the stirrup maintenance the vaporizer can be put on a horizontal plain. After passing the check, put it on the stirrup |
| 5. The vaporizer flashes the heating | The electronic vaporizer (desflurane) did not reach the proper temperature | Wait the proper time to reach the optimal temperature. Inform the anesthesiologist and administer intravenous agents while waiting |
| 6. On the vaporizer there is the gas reserve alarm but the sentinel column is full enough | The electronic vaporizer is on a stirrup that is not in axis, and the reading level on the sentinel column is altered | While waiting for the stirrup maintenance, the vaporizer must be reloaded independently of the sentinel column level |
| 7. Alarm during the operation of the electronic vaporizer (desflurane) knob | Electronic vaporizer not connected to the electric current | Connect it to the electric current trough a functioning socket |
| 8. Vaporizer knob is blocked | The nonelectronic vaporizer gas run out the gas | Reload the vaporizer |
| 9. Sentinel column of the nonelectronic vaporizer is sufficient but the inhale fraction is zero | The nonelectronic vaporizer is empty but is positioned on a bar that is not in axis and this alters the reading level on the sentinel | While waiting for the stirrup maintenance, the vaporizer must be reloaded independently of the sentinel column level |
| 10. EtCO₂ curve present but the reading of the exhale halogenates fraction is zero | The vaporizer is turned off | Turn it on according to the protocol |
| 11. EtCO₂ curve present but the reading of the exhale halogenates fraction is zero even though the vaporizer is turned on | The vaporizer is not working | Monitor the inhale gas fraction, if it does not detect any value of halogenate see problem point-2d, point-2e, point-2g, and point-9 |
| 12. Exhale gas leakage (halogenates included) from the additional discharge doors | The bayonet socket of venturi was not correctly placed in the discharge door on the wall | Place it in the proper way and make sure that the light-emitted diode, if present, is switched on |
Neto, et al.: Volatile agents in cardiopulmonary bypass

During the use of the volatile agents in CPB, it is very important to analyze all gases that come in and go out of the membrane oxygenators. The proper monitoring of inhaled and exhaled fraction of the gas allows not only the monitoring of anesthesia level, but also to detect possible leakage in the circuit. Nevertheless, most current oxygenators have redundant venting systems that eliminate the hazards of potential over pressurization inside the oxygenator which makes it difficult to measure precisely the volatile anesthetic levels in the exhaust port. In a prospective observational study, changes in sevoflurane plasma concentrations (SPCs) and bispectral index values during CPB were evaluated together with patient temperature, hemodilution, oxygenator fresh gas flow, and sevoflurane concentration in the exhaust gas from the oxygenator. This study evidenced that SPCs were higher during hypothermia and with an increased fresh gas flow in oxygenator, while were lower with hemodilution. No correlation was found between SPCs and the concentration of sevoflurane in the oxygenator exhaust port gas, suggesting that leakages occurred from the main port during measurements. Moreover, most scavenging system devices used during this technique to evacuate the volatile gases from the operating room could be the cause of the reading line failure during monitoring.

Table 1: Contd...

| Problem | Cause | Solution |
|---------|-------|----------|
| 13. Venturi manometer on the zero position | The venturi bayonet not correctly placed in the wall socked | Place it properly and make sure that the light-emitting diode (if present) is turned on |
| | The discharge door is not working | IF pushing manually the valve of the discharge door on the wall you cannot feel any suction, stop the halogenate protocol |
| | Obstruction of the rubber tube that runs from the wall discharge door to the Venturi | Remove the obstacle |
| | The venturi could have been connected to the secondary discharge door of the oxygen-gas | Check in vitro which is the main oxygen discharge door in doubt |

ETCO\(_2\): End-tidal carbon dioxide

During the use of the volatile agents in CPB, at first, the fresh gas flow from the blender enters into the calibrated vaporizer and is mixed with a desired concentration of the volatile agent. After that, the fresh gas flow, now mixed with a vaporized volatile agent, and enters into the circuit of the membrane oxygenator [Figure 1]. Many companies fail to mention that vaporizers can be included in their circuit and that the volatile agents can be used with standard membrane oxygenators.

![Figure 1: Schematic representation of the use of volatile agents adapted to cardiopulmonary bypass machine](image)
Any volatile agent in the membrane oxygenator is supposed to pollute the operating theater. This is the major reason why proper scavenging systems are always necessary when this technique is used. The exposure limit for halogenated anesthetics is on average 2 parts per million (ppm), and it slightly changes according to the average over the period of anesthetic administration. It is important to mention that the olfactory thresholds typically is much higher than the 2 ppm.\(^{[11]}\)

Recently, Nigro Neto \textit{et al.}\(^{[8]}\) described in a systematic review that the most serious accidents associated to the use of volatile agents during CPB are pollution of the room and cracks in the polycarbonate shell of the extracorporeal circuit components caused by spilled liquid volatile agent. Awareness is rare and seems to be associated to the type of membrane oxygenator used. Currently, there are two groups of hollow-fiber membrane oxygenators used in clinical practice [Table 2].\(^{[12]}\) The first type includes hollow-fiber membranes, primarily composed of microporous polypropylene, which is widely for standard CPB without having performances affected by the use of volatile agents.\(^{[9]}\) The second type (diffusion plasma-resistant oxygenators) has the basic membrane compounded primarily of poly-(4-methyl-1-pentene). This type is increasingly used for extracorporeal life support or extracorporeal membrane oxygenation, and might increase the risk of intraoperative awareness during CPB by lowering the transfer of the volatile agent to the blood.\(^{[13,14]}\) To avoid this undesirable event, it is important to monitor the consciousness depth by monitoring systems such as bispectral index scale or by extrapolating plasma concentration from measured end-tidal anesthetic gas concentrations.\(^{[10]}\) Moreover, proper scavenging system is utmost important along with strict patient monitoring during the delivery of these agents. Unlike bubble oxygenators (which rely on direct contact of blood and bubbles for gas exchange and are designed to separate undissolved gas from blood before the blood exits the oxygenator), membrane oxygenators are not designed to separate blood and bubbles of undissolved gas. Consequently, if large volumes of undissolved gas enter into the blood or are generated by back pressure in the membrane oxygenator, these will flow out of the oxygenator with blood. The potential for gas embolism exists if the outlet gas vent port of these oxygenators becomes either partially or totally occluded. Gas scavenging systems for these oxygenators must not cause the application of positive or negative pressures in the gas jackets as this may be dangerous. The American National Standards Institute (ANSI) standard (ANSI Z79.11) addressing scavenging systems for anesthetic gases apply to oxygenators as well as to anesthesia machines. This standard states that scavengers must not generate positive pressures exceeding 10 cm of water (7.4 mmHg) or negative pressures exceeding 0.5 cm of water (0.37 mmHg).\(^{[15]}\)

**CONCLUSION**

While waiting for industry upgrades, we recommend that volatile agents should be used during CPB only by skilled perfusionists and physicians with the aim to reduce postoperative morbidity and mortality.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**REFERENCES**

1. Nordén I. The influence of anaesthetics on systemic vascular resistance during cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1974;8:81-7.
2. Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, D’Avolio S, Marchetti C, \textit{et al.} Desflurane and sevoflurane in cardiac surgery: A meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007;21:502-11.
3. Bignami E, Biondi-Zoccai G, Landoni G, Fochi O, Testa V, Sheiban I, \textit{et al.} Volatile anesthetics reduce mortality in cardiac surgery. J Cardiothorac Vasc Anesth 2009;23:594-9.
4. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007;21:664-71.
5. Landoni G, Rodseth RN, Santini F, Ponschab M, Ruggeri L, Székely A, \textit{et al.} Randomized evidence for reduction of perioperative mortality. J Cardiothorac Vasc Anesth 2012;26:764-72.
6. Likhvantsev VV, Landoni G, Levikov D. Sevoflurane versus total intravenous anesthesia for isolated coronary artery bypass surgery with cardiopulmonary bypass: A randomized trial. J Cardiothorac Vasc Anesth 2016. Available from: http://dx.doi.org/10.1053/j. pvca.2016.02.030. [Last accessed on 2016 Feb 27].
7. De Hert SG, Van der Linden PJ, Cromheecke S, Meeus R,
Nelis A, Van Reeth V, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004;101:299-310.
8. Nigro Neto C, Landoni G, Cassarà L, De Simone F, Zangrillo A, Tardelli MA. Use of volatile anesthetics during cardiopulmonary bypass: A systematic review of adverse events. J Cardiothorac Vasc Anesth 2014;28:84-9.
9. Nigro Neto C, Arnoni R, Rida BS, Landoni G, Tardelli MA. Randomized trial on the effect of sevoflurane on polypropylene membrane oxygenator performance. J Cardiothorac Vasc Anesth 2013;27:903-7.
10. Nitzschke R, Wilgusch J, Kersten JF, Trepte CJ, Haas SA, Reuter DA, et al. Changes in sevoflurane plasma concentration with delivery through the oxygenator during on-pump cardiac surgery. Br J Anaesth 2013;110:957-65.
11. National Institute of Occupational Safety and Health. NIOSH Pocket Guide to Chemical Hazards. Washington, DC: US Government Printing Office; 1994.
12. Gleen PG. Cardiopulmonary Bypass Principles and Practice. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 47-9.
13. Philipp A, Wiesenack C, Behr R, Schmid FX, Birnbaum DE. High risk of intraoperative awareness during cardiopulmonary bypass with isoflurane administration via diffusion membrane oxygenators. Perfusion 2002;17:175-8.
14. Wiesenack C, Wiesner G, Keyl C, Gruber M, Philipp A, Ritzka M, et al. In vivo uptake and elimination of isoflurane by different membrane oxygenators during cardiopulmonary bypass. Anesthesiology 2002;97:133-8.
15. Hazard. Scavenging gas from membrane oxygenators. Health Devices 1987;16:343-4. Available from: http://www.mdsr.ecri.org/summary/detail.aspx?doc_id=8093. [Last accessed on 2015 Sep 09].